Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

ConditionsRecurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Recurrent Malignant Solid Neoplasm Clonal Cytopenia of Undetermined Significance Clonal Hematopoiesis Idiopathic Cytopenia of Undetermined Significance Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder Ovarian Carcinoma Myeloid Neoplasm Post Cytotoxic Therapy

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorUniversity of Washington

About this trial

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Eligibility criteria

Qualifiers

Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy

At least 4 months of exposure to a PARP inhibitor

Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm

Disqualifiers

Individuals with a life expectancy of less than 6 months

Trial design

Treatments tested in this trial

Non-Interventional Study

Treatment groups

2,000 Participants

are divided into 1 treatment group

Locations

Fred Hutch/University of Washington Cancer Consortium98109, SeattleWashington, United States

Sponsors and collaborators

University of Washington

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov